Date | Insider | Price | Amount |
---|---|---|---|
8-18-2023 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$9.00 CAGR » |
$16,000,002.00 1,777,778 shares |
5-15-2023 Insider Buy |
Eric Easom Chief Executive Officer |
$5.38 CAGR » |
$53,770.00 10,000 shares |
7-27-2022 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$7.78 CAGR » |
$180,674.69 23,219 shares |
3-29-2022 Insider Buy |
Adjuvant Global Health Technology Fund, L.P. >10% Owner |
$15.00 CAGR » |
$2,499,990.00 166,666 shares |
3-29-2022 Insider Buy |
Kabeer Aziz Director and >10% Owner |
$15.00 CAGR » |
$2,499,990.00 166,666 shares |
3-29-2022 Insider Buy |
Robin Shane Readnour Director |
$15.00 CAGR » |
$2,300,010.00 153,334 shares |
3-29-2022 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$15.00 CAGR » |
$24,999,990.00 1,666,666 shares |
Also See: Institutional Holders of ANTX
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 08/21/2023 | |
End date: | 05/10/2024 | |
Start price/share: | $13.75 | |
End price/share: | $2.42 | |
Dividends collected/share: | $0.00 | |
Total return: | -82.40% | |
Annualized Gain: | -114.36% | |
Starting investment: | $10,000.00 | |
Ending investment: | $1,760.00 | |
Years: | 0.72 |
An2 Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent An2 Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ANTX
Free ANTX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |